Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer

BACKGROUND: We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GEMOX) resulted in greater antitumor activity and might be a treatment option for patients with biliary tract cancers (BTCs). Molecular subgroup analysis of treatment outcomes in patients who had speci...

Full description

Bibliographic Details
Main Authors: Seung Tae Kim, Kee-Taek Jang, Jeeyun Lee, Heung-Moon Jang, Hye-Jin Choi, Hye-Lim Jang, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Joon Oh Park
Format: Article
Language:English
Published: Elsevier 2015-02-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523314001375

Internet

http://www.sciencedirect.com/science/article/pii/S1936523314001375

Similar Items